Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
SUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES Generic DOXYCYCLINE MONOHYDRATE, DELAYED RELEASE TETRACYCLINE PRODUCTS Brand HICL GCN Exception/Other ADOXA, 7184, 19107, 40363, 25751, 98818, DOXYCYCLINE HYCLATE DORYX DOXYCYCLINE MONOHYDRATE MONODOX DOXYCYCLINE MONOHYDRATE MINOCYCLINE HCL ORACEA SOLODYN 25283, 25284, 34586, 38752 99828 98271, 40651, 40652 27097 26957, 26958, 26960, 27396, 27397, 29040, 29044, 29045 GUIDELINES FOR USE 1. Is the patient a new enrollee within the past 6 months; (NOTE: Confirm eligibility information that the patient has enrolled within the past 6 months and document enrollment date.)? If yes, continue to #2. If no, continue to #3. 2. Is there medical record documentation (for example, chart notes) or claims history that the patient has been prescribed and is currently stabilized on this medication; (NOTE: Document that the patient is a new enrollee and is currently stable on this medication in the PA Comments.)? If yes, Approve for 12 months. If no, continue to #3. 3. Does the patient’s prescription history show claims for brand name Adoxa, Doryx, Monodox, Oracea, or Solodyn within the past 120 days; (NOTE: previous claims for generic products do not automatically qualify a member for the brand product. Document that the patient's prescription history shows claims for the requested brand drug (Adoxa, Doryx, Monodox, Oracea, or Solodyn) within the past 120 days in the PA Comments.)? If yes, Approve for 12 months. If no, continue to #4. CONTINUED ON NEXT PAGE Revised 12/7/2015 Page 1 of 2 SUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES DELAYED RELEASE TETRACYCLINE PRODUCTS GUIDELINES FOR USE (CONTINUED) 4. Can the prescriber provide documentation that the patient has tried and failed treatment (after at least 6 weeks of continuous therapy) with or has a contraindication to generic doxycycline monohydrate OR doxycycline hyclate, (Vibramycin, Vibra-Tab), AND minocycline (Minocin, Myrac, Dynacin); (NOTE: Document prior drugs and dates prescription provided in tried/failed field.)? If yes, Approve for 12 months. If no, do not approve. DENIAL TEXT: Our guideline for Delayed-Released Tetracyclines, requires that the patient has tried and failed treatment or has a contraindication to generic doxycycline monohydrate, doxycycline hyclate, (Vibramycin, Vibra-Tab) AND minocycline (Minocin, Myrac, Dynacin). REFERENCES • Adoxa prescribing information, Pharma Derm, Melville, NY, March 2008. • Facts and Comparisons Online Edition, Accessed 12/13/10 • Oracea prescribing information, Galderma Laboratories, Fort Worth, TX, May 2008. • Solodyn prescribing information, Medicis, Scottsdale, AZ, 2010. Commercial X HIEx X Created: 05/05/11 Effective Revised 12/7/2015 Client Approval: P&T Approval: Page 2 of 2